SEC Form 4 · accession 0001144204-16-109522
BRAINSTORM CELL THERAPEUTICS INC. · BCLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alon Pinkas
Director
Period of report
Jun 22, 2016
Accepted (ET)
Jun 23, 2016 · 5:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001137883
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.75 | Jun 22, 2016 | A | 15,333 | A | Jul 22, 2016 | Jun 22, 2026 | Common Stock | 15,333 | 15,333 | D |
Explanation of responses
- F1Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on July 22, 2016 until fully vested and exercisable on June 22, 2017, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.